Vebreltinib by Apollomics for Renal Cell Carcinoma: Likelihood of Approval

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vebreltinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vebreltinib overview

APL-101 (CBT-101) is under development for the treatment of c-Met dysregulation advanced solid tumors such as high-grade gliomas, non-small cell lung cancer, gastric cancer, gastroesophageal junction adenocarcinoma, renal cell carcinoma, gastric cancer,  hepatic cancer, glioblastoma multiforme, pancreatic cancer, glioblastoma multiforme. The therapeutic candidate is administered orally as a capsule. It acts by targeting the c-Met (hepatocyte growth factor receptor). It was also under development for the treatment of advanced or metastatic hepatocellular carcinoma, renal cell carcinoma.

Apollomics overview

Apollomics formerly CBT Pharmaceuticals, is a biotechnology company that discovers and develops oncology therapies. It is investigating APL-101, a novel small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in gastric, hepatic, pancreatic and lung tumors; and APL-102, an oral multi kinase inhibitor (mKi) targeting receptor tyrosine kinase (RTKs) and serine or threonine-kinases in liver, breast, colorectal, gastric cancers. The company is also evaluating APL-106 against acute myeloid leukemia (AML); APL-108 to treat multiple myeloma (MM); APL-501 and APL-102 targeting solid tumors; APL-502 and APL-801 against multiple tumors; and APL-810 for gastroenterological cancers. It operates in Taiwan and the US. Apollomics is headquartered in Pleasanton, California, the US.

For a complete picture of Vebreltinib’s drug-specific PTSR and LoA scores, buy the report here.